As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Management believes these developments will position EYLEA HD as the new standard of care in the anti-VEGF ... chronic spontaneous urticaria and bullous pemphigoid in 2025. Q4 2024 diluted net ...

An England-wide study of 331 rare diseases in over 58 million people co-led by UCL researchers has identified eight rare diseases that carry ...

Libtayo became Regeneron's latest blockbuster product in 2024, and we are looking to build on that by expanding shared metastatic non-melanoma skin cancers ... for bullous pemphigoid late last ...

These further elevate the number of cases and require active health care systems to develop and implement ... for a potential shift in the treatment of Bullous Pemphigoid, a rare and debilitating ...